Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
2.
J Pediatr Surg ; 59(5): 752-756, 2024 May.
Article in English | MEDLINE | ID: mdl-38368197

ABSTRACT

Abdominal metastatic disease is a nearly universal feature of Desmoplastic Small Round Cell Tumor. The presence of this large tumor burden can be dissuasive to surgeons. Aggressive attempts at resection of all of the dozens to hundreds of nodules in the abdomen are often fraught with difficulty. This author has operated on over 200 patients with Desmoplastic Small Round Cell Tumor and offers technical considerations that aid in complete removal of all intraabdominal tumors (sarcomatosis) with an organ sparing approach. The most challenging portion of the operation is resection of the pelvic tumor in the pouch of Douglas without removing either the bladder or the rectum. These tumors are almost always large and adherent to the bladder and rectum. The desired result should be a partial peritonectomy without any evidence of gross, visible disease.


Subject(s)
Abdominal Neoplasms , Desmoplastic Small Round Cell Tumor , Pelvic Neoplasms , Humans , Desmoplastic Small Round Cell Tumor/surgery , Abdominal Neoplasms/surgery , Abdominal Neoplasms/pathology , Pelvis , Rectum/pathology
5.
Tumori ; 108(1): 93-97, 2022 Feb.
Article in English | MEDLINE | ID: mdl-33594944

ABSTRACT

This study reports the treatment feasibility and efficacy of a novel multiagent intensive treatment program for young patients with desmoplastic small round cell tumor. This small series includes three patients and should be seen as a first suggestion of integration of the dose density and the maintenance chemotherapy concept. The IrIVA regimen (irinotecan, ifosfamide, vincristine, and actinomycin-D) is added-used at a short interval between chemotherapy administrations-at more classic intensive ifosfamide-based regimens. The vinorelbine and low-dose oral cyclophosphamide maintenance therapy is added at the end of conventional chemotherapy to achieve an antiangiogenic effect.


Subject(s)
Dactinomycin/administration & dosage , Desmoplastic Small Round Cell Tumor/drug therapy , Ifosfamide/administration & dosage , Irinotecan/administration & dosage , Vincristine/administration & dosage , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Child , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Dactinomycin/adverse effects , Desmoplastic Small Round Cell Tumor/pathology , Desmoplastic Small Round Cell Tumor/surgery , Dose-Response Relationship, Drug , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Humans , Ifosfamide/adverse effects , Irinotecan/adverse effects , Male , Treatment Outcome , Vincristine/adverse effects , Vinorelbine/administration & dosage , Vinorelbine/adverse effects , Young Adult
6.
Indian J Pathol Microbiol ; 64(1): 206-209, 2021.
Article in English | MEDLINE | ID: mdl-33433447

ABSTRACT

Desmoplastic small round cell tumor (DSRCT) is a rare, aggressive neoplasm of uncertain histogenesis that preferentially involves the abdominal and pelvic cavities. DSRCT mainly develops in adolescent and young adults with a strong male predominance; the male to female ratio is 4:1. Ovarian location is exceptional. DSRCT generally develops in the abdomen and have a tendency towards peritoneal spread, with subsequent metastasis to distant lymph nodes, liver and lungs. It is a poorly understood malignancy with a very characteristic morphology, immunophenotype, cytogenetic features, and poor prognosis. This tumor can co-express epithelial, neuronal, and mesenchymal markers. Despite intensive therapy, including surgery, radiotherapy and chemotherapy, and immunotherapy; the 5-year survival is less than 15%.


Subject(s)
Desmoplastic Small Round Cell Tumor/diagnostic imaging , Ovarian Neoplasms/diagnostic imaging , Ovary/pathology , Abdominal Neoplasms/diagnostic imaging , Abdominal Neoplasms/surgery , Desmoplastic Small Round Cell Tumor/pathology , Desmoplastic Small Round Cell Tumor/surgery , Female , Humans , Immunohistochemistry , Ovarian Neoplasms/surgery , Prognosis , Tomography, X-Ray Computed , Young Adult
8.
AJR Am J Roentgenol ; 212(3): W45-W54, 2019 03.
Article in English | MEDLINE | ID: mdl-30673334

ABSTRACT

OBJECTIVE: The purpose of this study is to evaluate the clinical, pathologic, and multimodality cross-sectional imaging features of a cohort of 94 patients with desmoplastic small round cell tumor (DSRCT). MATERIALS AND METHODS: This retrospective study of 94 patients with pathologically verified DSRCT was conducted at a tertiary cancer center between 2001 and 2013. Epidemiologic, clinical, pathologic, and imaging findings were recorded. Tumor size, location, and shape and the distribution pattern of metastases at presentation were analyzed. RESULTS: DSRCT most often occurred in young patients (median age, 21.5 years; range, 5-53 years), showing a marked predominance in male patients (86 male patients vs eight female patients). Eighty nine-patients (95%) were white (defined in this study as white or Hispanic), four were African American, and one was of Asian descent. Most patients had symptoms, with abdominal pain noted as the most common symptom. At initial presentation, 85 patients (90%) had multifocal disease, nodular disease, diffuse omental and peritoneal disease, or a combination of these conditions. Thirty-eight patients (40%) had diaphragmatic involvement. Thirty-two patients (34%) had liver metastases, and 49 patients (52%) had retroperitoneal involvement in the form of implants, tumoral extension, or nodal involvement. With regard to thoracic findings, 33 patients (35%) had nodal disease, 17 (18%) had pleural effusions, and only two (2%) had lung metastases at presentation. Twelve patients (13%) had calcified lesions. CONCLUSION: DSRCT is a rare, multifocal peritoneal malignancy with frequently disseminated abdominal disease at presentation. In the abdomen, disease most commonly involves the omentum and peritoneum, followed by the retroperitoneum. The liver is the most common solid visceral metastatic site. A substantial number of patients have diaphragmatic involvement. In the thorax, nodal and pleural involvement is more common than lung involvement.


Subject(s)
Abdominal Neoplasms/diagnostic imaging , Desmoplastic Small Round Cell Tumor/diagnostic imaging , Abdominal Neoplasms/pathology , Abdominal Neoplasms/surgery , Adolescent , Adult , Child , Child, Preschool , Desmoplastic Small Round Cell Tumor/pathology , Desmoplastic Small Round Cell Tumor/surgery , Female , Humans , Male , Middle Aged , Retrospective Studies , Sex Factors
9.
Int Ophthalmol ; 39(2): 471-475, 2019 Feb.
Article in English | MEDLINE | ID: mdl-29383463

ABSTRACT

PURPOSE: Desmoplastic small round cell tumor is a rare malignant neoplasm that most often occurs in the abdomen or pelvis of young men. We herein describe a rare case of desmoplastic small round cell tumor arising from the left orbit in a 16-year-old male. METHODS AND RESULTS: A biopsy was performed and the histology showed the nests of tumor cells with small round cell morphology. The tumor cells showed immunopositivity for desmin, CD99, CD56, SMA, NSE, CgA, SYN, Ki67 and vimentin. Fluorescence in situ hybridization study using EWSR1 break-apart probe was positive for EWSR1 gene rearrangement. After complete surgical resection of the tumor, we did not find tumor recurrence or metastasis with one-year follow-up. Furthermore, a review of the relevant English literature has been discussed. CONCLUSIONS: In the present study, for the first time, we report a case of desmoplastic small round cell tumor which is located in the orbital region.


Subject(s)
Desmoplastic Small Round Cell Tumor/diagnosis , Orbital Neoplasms/diagnosis , Biomarkers, Tumor/analysis , Biopsy , Desmoplastic Small Round Cell Tumor/metabolism , Desmoplastic Small Round Cell Tumor/surgery , Humans , Ophthalmologic Surgical Procedures/methods , Orbital Neoplasms/metabolism , Orbital Neoplasms/surgery , Tomography, X-Ray Computed
10.
Clin Cancer Res ; 24(19): 4865-4873, 2018 10 01.
Article in English | MEDLINE | ID: mdl-29871905

ABSTRACT

Purpose: Desmoplastic small round cell tumor (DSRCT), which harbors EWSR1-WT1 t(11;22)(p13:q12) chromosomal translocation, is an aggressive malignancy that typically presents as intra-abdominal sarcomatosis in young males. Given its rarity, optimal treatment has not been defined.Experimental Design: We conducted a retrospective study of 187 patients with DSRCT treated at MD Anderson Cancer Center over 2 decades. Univariate and multivariate regression analyses were performed. We determined whether chemotherapy, complete cytoreductive surgery (CCS), hyperthermic intraperitoneal cisplatin (HIPEC), and/or whole abdominal radiation (WART) improve overall survival (OS) in patients with DSRCT. Critically, because our institutional practice limits HIPEC and WART to patients with less extensive, potentially resectable disease that had benefited from neoadjuvant chemotherapy, a time-variant analysis was performed to evaluate those adjunct treatment modalities.Results: The pre-2003 5-year OS rate of 5% has substantially improved to 25% with the advent of newer chemotherapies and better surgical and radiotherapy techniques (HR, 0.47; 95% CI, 0.29-0.75). Chemotherapy response (log rank P = 0.004) and CCS (log rank P < 0.0001) were associated with improved survival. Although WART and HIPEC lacked statistical significance, our study was not powered to detect their potential impact upon OS.Conclusions: Improved 3- and 5-year OS were observed following multidisciplinary treatment that includes Ewing sarcoma (ES)-based chemotherapy and complete tumor cytoreductive surgery, but few if any patients are cured. Prospective randomized studies will be required to prove whether HIPEC or WART are important. In the meantime, chemotherapy and CCS remain the cornerstone of treatment and provide a solid foundation to evaluate new biologically targeted therapies. Clin Cancer Res; 24(19); 4865-73. ©2018 AACR.


Subject(s)
Cytoreduction Surgical Procedures , Desmoplastic Small Round Cell Tumor/drug therapy , Sarcoma, Ewing/drug therapy , Adult , Combined Modality Therapy , Desmoplastic Small Round Cell Tumor/genetics , Desmoplastic Small Round Cell Tumor/pathology , Desmoplastic Small Round Cell Tumor/surgery , Disease-Free Survival , Female , Humans , Male , RNA-Binding Protein EWS/genetics , Sarcoma, Ewing/genetics , Sarcoma, Ewing/pathology , Sarcoma, Ewing/surgery , Young Adult
11.
Curr Oncol Rep ; 19(12): 80, 2017 Oct 18.
Article in English | MEDLINE | ID: mdl-29043531

ABSTRACT

Desmoplastic small round cell tumor (DSRCT) is a rare tumor that was first described by Gerald and Rosai in 1989 as a mesenchymal entity. This tumor has a unique translocation t (11:22) (p:13, q:12) resulting in EWS/WT1 gene fusion that is diagnostic for DSCRT. The overall prognosis for desmoplastic small round cell tumor remains extremely poor, with reported rates of death as high as 90%. Although the majority of patients undergo chemotherapy following surgery, the prognosis has been shown to be independent of whether the surgical process preceded or followed chemotherapy. In this review, we provide insights for the management of DSCRT that requires aggressive multimodality therapy.


Subject(s)
Desmoplastic Small Round Cell Tumor/drug therapy , Oncogene Proteins, Fusion/genetics , Prognosis , Combined Modality Therapy , Desmoplastic Small Round Cell Tumor/genetics , Desmoplastic Small Round Cell Tumor/surgery , Humans , Translocation, Genetic/genetics
12.
PLoS One ; 12(2): e0171639, 2017.
Article in English | MEDLINE | ID: mdl-28234908

ABSTRACT

BACKGROUND: Desmoplastic Small Round Cell Tumor (DSRCT) is a rare disease affecting predominantly children and young adults and for which the benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) after complete cytoreductive surgery (CCRS) remains unknown. METHODS: To identify patients with DSRCT without extraperitoneal metastases (EPM) who underwent CCRS between 1991 and 2015, a retrospective nation-wide survey was conducted by crossing the prospective and retrospective databases of the French Network for Rare Peritoneal Malignancies, French Reference Network in Sarcoma Pathology, French Sarcoma Clinical Network and French Pediatric Cancer Society. RESULTS: Among the 107 patients with DSRCT, 48 had no EPM and underwent CCRS. The median peritoneal cancer index (PCI) was 9 (range: 2-27). Among these 48 patients, 38 (79%) had pre- and/or postoperative chemotherapy and 23 (48%) postoperative whole abdominopelvic radiotherapy (WAP-RT). Intraperitoneal chemotherapy was administered to 11 patients (23%): two received early postoperative intraperitoneal chemotherapy (EPIC) and nine HIPEC. After a median follow-up of 30 months, the median overall survival (OS) of the entire cohort was 42 months. The 2-y and 5-y OS were 72% and 19%. The 2-y and 5-y disease-free survival (DFS) were 30% and 12%. WAP-RT was the only variable associated with longer peritoneal recurrence-free survival and DFS after CCRS. The influence of HIPEC/EPIC on OS and DFS was not statistically conclusive. CONCLUSION: The benefit of HIPEC is still unknown and should be evaluated in a prospective trial. The value of postoperative WAP-RT seems to be confirmed.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cytoreduction Surgical Procedures , Desmoplastic Small Round Cell Tumor/therapy , Hyperthermia, Induced/methods , Peritoneal Neoplasms/therapy , Adolescent , Adult , Child , Child, Preschool , Combined Modality Therapy , Desmoplastic Small Round Cell Tumor/mortality , Desmoplastic Small Round Cell Tumor/pathology , Desmoplastic Small Round Cell Tumor/surgery , Doxorubicin/therapeutic use , Female , Gamma Rays/therapeutic use , Humans , Ifosfamide/therapeutic use , Male , Middle Aged , Neoplasm Staging , Peritoneal Neoplasms/mortality , Peritoneal Neoplasms/pathology , Peritoneal Neoplasms/surgery , Peritoneum/drug effects , Peritoneum/pathology , Peritoneum/radiation effects , Peritoneum/surgery , Prospective Studies , Retrospective Studies , Survival Analysis , Treatment Outcome
13.
Int J Radiat Oncol Biol Phys ; 95(4): 1244-53, 2016 07 15.
Article in English | MEDLINE | ID: mdl-27354131

ABSTRACT

PURPOSE: To identify the prognostic role of adjuvant abdominal radiation therapy (RT) on oncologic outcomes as a part of multimodal treatment in the management of desmoplastic small round cell tumor (DSRCT) and to determine its impact according to the quality of surgical resection. METHODS AND MATERIALS: All patients treated for primary abdominal DSRCT in 8 French centers from 1991 to 2014 were included. Patients were retrospectively staged into 3 groups: group A treated with adjuvant RT after cytoreductive surgery, group B without RT after cytoreductive surgery, and group C by exclusive chemotherapy. Peritoneal progression-free survival (PPFS), progression-free survival (PFS), and overall survival (OS) were evaluated. We also performed a direct comparison between groups A and B to evaluate RT after cytoreductive surgery. Radiation therapy was also evaluated according to completeness of surgery: complete cytoreductive surgery (CCS) or incomplete cytoreductive surgery (ICS). RESULTS: Thirty-seven (35.9%), thirty-six (34.9%), and thirty (28.0%) patients were included in groups A, B, and C, respectively. Three-year OS was 61.2% (range, 41.0%-76.0%), 37.6% (22.0%-53.1%), and 17.3% (6.3%-32.8%) for groups A, B, and C, respectively. Overall survival, PPFS, and PFS differed significantly among the 3 groups (P<.001, P<.001, and P<.001, respectively). Overall survival and PPFS were higher in group A (RT group) compared with group B (no RT group) (P=.045 and P=.006, respectively). Three-year PPFS was 23.8% (10.3%-40.4%) for group A and 12.51% (4.0%-26.2%) for group B. After CCS, RT improved PPFS (P=.024), but differences in OS and PFS were not significant (P=.40 and P=.30, respectively). After ICS, RT improved OS (P=.044). A trend of PPFS and PFS increase was observed, but the difference was not statistically significant (P=.073 and P=.076). CONCLUSIONS: Adjuvant RT as part of multimodal treatment seems to confer oncologic benefits for patients treated for abdominal DSRCT after cytoreductive surgery and perioperative chemotherapy.


Subject(s)
Abdominal Neoplasms/radiotherapy , Desmoplastic Small Round Cell Tumor/radiotherapy , Abdominal Neoplasms/mortality , Abdominal Neoplasms/surgery , Adolescent , Adult , Child , Child, Preschool , Combined Modality Therapy , Desmoplastic Small Round Cell Tumor/mortality , Desmoplastic Small Round Cell Tumor/surgery , Female , Humans , Male , Middle Aged , Radiotherapy, Adjuvant , Retrospective Studies
15.
Cir Cir ; 83(3): 243-8, 2015.
Article in Spanish | MEDLINE | ID: mdl-26055279

ABSTRACT

BACKGROUND: The desmoplastic small round cell tumour is a rare and aggressive intra-abdominal neoplasia, with only 200 cases reported, and a higher incidence in men and predilection for the second decade of life. Histologically characterized by the presence of small nests of undifferentiated tumour cells, wrapped in fibrous desmoplastic stroma. CLINICAL CASE: A 24 year old male started with abdominal pain of 4 weeks onset in the right upper quadrant, colic type, sporadic, self-limiting and accompanied by early satiety, decreased appetite, and involuntary weight loss of 10 kg in 3 months. At the time of admission the abdomen was globular, with decreased peristalsis, soft, depressible. Computed tomography of the abdomen showed multiple enlarged lymph nodes in the abdominal-pelvic cavity. A laparotomy was performed, with a subsequent omentum resection due to the presence of multiple tumours, which microscopically were characterised by groups of small, round, blue cells, separated by a desmoplastic stroma. The immunohistochemistry was positive for desmin (> 75%), epithelial membrane antigen (> 75%), CD99 (> 50%), and S100 (25%), concluding with an abdominal tumour of small, round, blue cells as a diagnosis. Chemotherapy treatment was initiated based on IMAP plus GM-CSF. CONCLUSIONS: The desmoplastic small round cell tumour is a rare neoplasia, with diagnostic complexity and a lethal course. Its clinical presentation is unspecific. Histologically, it is classified as an aggressive soft tissue sarcoma that shares similar characteristics with the family of the small and blue cells tumours.


Subject(s)
Abdominal Neoplasms , Desmoplastic Small Round Cell Tumor , Abdominal Neoplasms/pathology , Abdominal Neoplasms/surgery , Desmoplastic Small Round Cell Tumor/pathology , Desmoplastic Small Round Cell Tumor/surgery , Humans , Male , Young Adult
16.
Int Surg ; 100(5): 809-13, 2015 May.
Article in English | MEDLINE | ID: mdl-26011199

ABSTRACT

Desmoplastic small round cell tumor (DSRCT) is an extremely rare, highly aggressive, malignant tumor of undetermined histogenesis. Adolescent males are primarily affected with a typically abdominal or pelvic mass. Diagnosis is based on histologic analysis of biopsy and cytogenetic studies. Owing to the rarity of the tumor and the unusually aggressive presentation, treatment is challenging and has not been standardized. DSRCT has a very poor prognosis, with a median survival range of 17 to 25 months. In this work, we report a case of DSRCT in the transverse colon, which has never before been reported in the literature. Our case study is of a 30-year-old Chinese female who presented with a history of 6 months abdominal discomfort and fatigue. A palpable, hardly mobile mass was detected in the right lower quadrant abdomen by physical examination. Abdominal and pelvic magnetic resonance imaging revealed an 8.0 × 10.5 × 11.1-cm mass with no pulmonary and hepatic metastasis. The patient underwent exploratory laparotomy and transverse colectomy, which revealed a mass in the transverse colon and no metastasis in the peritoneum, greater omentum, or mesentery. Immunohistochemistry findings revealed positive staining for epithelial, mesenchymal, and neural markers, which confirmed the presentation of DSRCT. A 6-month postoperative follow-up failed to find any recurrence. DSRCT is a highly aggressive, malignant, mesenchymal tumor with a very poor prognosis. No consensus has been reached for the treatment protocol of DSRCT. However, debulking surgery with postoperative chemotherapy or radiotherapy might promise more optimistic results on survival.


Subject(s)
Colonic Neoplasms/diagnosis , Colonic Neoplasms/surgery , Desmoplastic Small Round Cell Tumor/diagnosis , Desmoplastic Small Round Cell Tumor/surgery , Adult , Colectomy , Colon, Transverse , Diagnosis, Differential , Female , Humans , Immunohistochemistry , Magnetic Resonance Imaging
17.
Clin Exp Metastasis ; 32(4): 369-81, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25822899

ABSTRACT

Despite improved therapy of advanced colorectal cancer, the median overall survival (OS) is still low. A surgical removal has significantly improved survival, if lesions are entirely removed. The purpose of this retrospective explorative study was to evaluate the prognostic value of histological growth patterns (GP) in chemonaive and patients receiving neo-adjuvant therapy. Two-hundred-fifty-four patients who underwent liver resection of colorectal liver metastases between 2007 and 2011 were included in the study. Clinicopathological data and information on neo-adjuvant treatment were retrieved from patient and pathology records. Histological GP were evaluated and related to recurrence free and OS. Kaplan-Meier curves, log-rank test and Cox regression analysis were used. The 5-year OS was 41.8% (95% CI 33.8-49.8%). Growth pattern evaluation of the largest liver metastasis was possible in 224 cases, with the following distribution: desmoplastic 63 patients (28.1%); pushing 77 patients (34.4%); replacement 28 patients (12.5%); mixed 56 patients (25.0%). The Kaplan-Meier analyses demonstrated that patients resected for liver metastases with desmoplastic growth pattern had a longer recurrence free survival (RFS) than patients resected for non-desmoplastic liver metastases (p=0.05). When patients were stratified according to neo-adjuvant treatment in the multivariate Cox regression model, hazard ratios for RFS compared to desmoplastic were: pushing (HR=1.37, 95% CI 0.93-2.02, p=0.116), replacement (HR=2.16, 95% CI 1.29-3.62, p=0.003) and mixed (HR=1.70, 95% CI 1.12-2.59, p=0.013). This was true for chemonaive patients as well as for patients who received neo-adjuvant treatment.


Subject(s)
Colorectal Neoplasms/pathology , Desmoplastic Small Round Cell Tumor/pathology , Liver Neoplasms/secondary , Neoplasm Recurrence, Local/pathology , Adult , Aged , Aged, 80 and over , Cell Proliferation , Combined Modality Therapy , Desmoplastic Small Round Cell Tumor/mortality , Desmoplastic Small Round Cell Tumor/surgery , Disease-Free Survival , Female , Hepatectomy , Humans , Liver/pathology , Liver/surgery , Liver Neoplasms/pathology , Liver Neoplasms/surgery , Male , Middle Aged , Neoplasm Recurrence, Local/surgery , Prognosis , Retrospective Studies , Survival Rate , Young Adult
19.
J Neurosurg ; 122(4): 773-7, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25479120

ABSTRACT

Desmoplastic small round cell tumors (DSRCTs) are rare, aggressive neoplasms that typically arise from abdominal and pelvic peritoneum in young adults. Other primary sites are uncommon, and an intracranial origin is exceptionally rare. Here the authors report the first case of a DSRCT presenting as a primary suprasellar tumor causing panhypopituitarism and severe bitemporal hemianopia in a young man. Macroscopic debulking of the tumor was undertaken, and histology revealed features of DSRCT. Reverse transcription polymerase chain reaction confirmed the presence of Ewing's sarcoma-Wilms tumor 1 (EWS-WT1) gene rearrangement specific to DSRCT. Postoperative whole-body imaging showed no primary malignancy elsewhere. The tumor recurred 4 months after surgery, and this was followed by cervical and mediastinal lymph node metastases. The patient died 20 months after initial presentation of rapidly progressive disease. DSRCTs should be included in the differential diagnosis of an unusual suprasellar mass in young adults. Early diagnosis is essential, and once the tumor is identified histologically, gross-total resection and radical postoperative treatment involving radiotherapy, chemotherapy, and close surveillance are required because of the lesion's potential for rapidly progressive malignancy.


Subject(s)
Brain Neoplasms/pathology , Desmoplastic Small Round Cell Tumor/pathology , Pituitary Neoplasms/pathology , Adult , Brain Neoplasms/surgery , Desmoplastic Small Round Cell Tumor/surgery , Fatal Outcome , Humans , Hypopituitarism/etiology , Male , Neurosurgical Procedures , Optic Chiasm/pathology , Pituitary Neoplasms/surgery , Sarcoma, Ewing/pathology , Sarcoma, Ewing/surgery , Vision Disorders/etiology , Visual Field Tests , Wilms Tumor/pathology , Wilms Tumor/surgery
20.
Neurocir. - Soc. Luso-Esp. Neurocir ; 25(6): 290-293, nov.-dic. 2014. ilus
Article in Spanish | IBECS | ID: ibc-130367

ABSTRACT

El liposarcoma mixoide de células redondeadas es un tumor habitualmente originado de partes blandas, que raramente encuentra su origen en el plexo braquial. Presentamos un caso muy infrecuente de liposarcoma mixoide de células redondeadas de plexo braquial que fue intervenido quirúrgicamente y que evolucionó favorablemente y sin focalidad neurológica tras 2 años de seguimiento. Es el primer caso publicado de esta estirpe oncológica originado en el plexo braquial


Myxoid/round cell liposarcoma is a soft tissue sarcoma that is extremely rare in the brachial plexus. We report a case of a myxoid/round cell liposarcoma originating in the brachial plexus that was surgically resected and evolved well, with no deficit or recurrence after 2 years of follow-up. To date, there has been no other case of this sarcoma in the literature


Subject(s)
Humans , Female , Middle Aged , Liposarcoma, Myxoid/surgery , Desmoplastic Small Round Cell Tumor/surgery , Brachial Plexus/pathology , Mesenchymal Stem Cells/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...